| MAGIC BULLET (CONTINUED) email:curepeyronies@yahoo.com |
 |
| |
 |
| |
 |
| |
 |
| |
 |
IN-1130 promotes the regression of fibrotic
plaque and restores elastin fibers. The area of
untreated Peyronies was assigned a value
equal for 100%. Each bar depicts the mean
values for 6 laboratory rats. The complete title
of this chart should be Plaque area (% PD
Group). The Control group is 0 because there
was no plaque area.
Wow! Where does one go to give these guys additional funding. For a man
with Peyronies this research article represents a potential breakthrough
treatment. (And I emphasize the word potential because the research is in the
early stages and has not been tested on humans). These laboratory rats had
only two treatments with IN-1130 and had a remarkable improvement. Who
knows what would have happened with additional treatment.
Almost one-half of all human medical deaths are somehow related to scar
tissue disorders. This substance, IN-1130, has been tested on other scar
tissue disease and has exhibited healing properties. According to Kidney
International, it suppresses renal fibrosis. TGF plays a central role in the
progression of renal fibrosis. IN-1130 significantly suppresses this
progression. It also may be a breakthrough treatment for prostate cancer.
According to the Journal of Urology, Volume 180, Issue 6, IN-1130
demonstrated an enhanced immune response to cancer cells and is a
potential prostate cancer treatment.
I am trying to get additional information on this substance. Who owns it? Is it
in the public domain for does a private company have a patent on it? Is there
additional Peyronies Disease testing planned? Stay tuned.
CLICK HERE FOR THE NEXT PAGE